State-of-the-Art Review : Increased Activated Protein C: Protein C Inhibitor Complex and Decreased Protein C Inhibitor Levels in Patients with Chronic Renal Failure on Maintenance Hemodialysis

Abstract

Hemostatic abnormalities were examined in 55 pa tients during maintenance hemodialysis (HD). Before HD, plasma protein C and protein S antigens were almost within the normal range, while plasma thrombin-antithrombin III complex (TAT III) and plasmin-plasmin inhibitor complex (PPIC) levels in HD patients were increased slightly, and plasminogen acti vator inhibitor 1 level was significantly increased, compared to that in normal volunteers. Plasma activated protein C (APC) and protein C inhibitor (PCI) complex and APC α1 antitrypsin (α1AT) complex were not detected in normal volunteers; how ever, plasma APC-PCI complex was increased in 36 of the patients and plasma APC-α1AT complex was increased in 25 patients. Plasma PCI levels in these patients before HD were significantly decreased. Plasma TAT, PPIC, and tissue type plasminogen activator levels were significantly higher before HD than after 1 hour HD and at the end of HD, while the changes in plasma protein C antigen, protein S antigen, PCI antigen, APC-PCI complex, and APC-α1AT complex were not significant after 1 hour of HD or at the end of HD compared to levels before HD. Plasma PCI levels were correlated with APC- PCI complex, suggesting that decreased PCI levels might be caused by the activation of protein C.

Keywords

Key Words: APC-PCI complex APC-α1AT complex Hemodialysis.

References

Bruton BT , Kruegar KK , Bryan FA National registry of longterm dialysis patients. JAMA 1971 ;218:718.

Brunner FP , Brynger H. , Chantler C. , et al. Combined report on regular dialysis and transplantation in Europe IX, 1978. In: Robinson BHB, Howkins JB, Naik RB, eds. Proceedings of the European Dialysis and Transplant Association 1979:7.

Deguchi K. , Izumi K. , Noguchi M. , et al. Coagulation and fibrinolysis in patients with chronic renal failure on maintenance hemodialysis. Acta Haematol JPN 1989;52:140.

Griffin JH , Evatt B. , Zimmerman T. , et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981;68:1370.

Comp PC , Nixon RR , Cooper MR , Esmon CT Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984;74:2082.

Esmon CT The regulation of natural anticoagulant pathways. Science 1987;235:1348.

Pelzer H. , Schwarz A. , Heinburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1987;59:101.

Mimuro J. , Koike Y. , Sumi Y. , Aoki N. Monoclonal antibodies to discrete regions in α2-plasmin inhibitor. Blood 1987;69:446.

Marlar RA , Endres-Brook J. , Miller C. Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation. Blood 1985;66:59.

10.

Tabernero D. , Espana F. , Vicente V. , et al. Protein C inhibitor and other components of the protein C pathway in patients with acute deep vein thrombosis during heparin treatment. Thromb Haemost 1990;63:380.

11.

Gruber A. Griffin JH Direct detection of activated protein C in blood from human subjects. Blood 1992;79:2340.

12.

Orthner CL , Kolen B. , Drohan WN A sensitive and facile assay for the measurement of activated protein C activity levels in vivo. Thromb Haemost 1993;69:441.

13.

Asakura H. , Saito M. , Ito K. , et al. Levels of thrombin-antithrombin III complex in plasma in cases of acute promyelocytic leukemia. Thromb Res 1988;50:895.

14.

Suzuki K. , Nishioka J. , Hashimoto S. Protein C inhibitor. Purification from human plasma and characterization. J Biol Chem 1983; 258:163.

15.

Suzuki K. , Stenflo J. , Dahlback B. Inactivation of human coagulation V by activated protein C. J Biol Chem 1983;258:1914.

16.

Suzuki K. , Nishioka J. , Hashimoto S. , et al. Normal titer of functional and immunoreactive protein C inhibitor in plasma of patients with congenital combined deficiency of factor V and factor VIII. Blood 1983;62:1266.

17.

Suzuki K. Biochemistry and Physiology of protein C inhibitor. In: Witt I , ed. Protein C-Biochemical and Medical Aspects. Berlin: Walter de Gruyter , 1985:43.

18.

Esmon CT The regulation of natural anticoagulant pathways. Science 1987;235:1348.

19.

Broekmana AW , Veltkamp JJ , Bertina RM Congenital protein C deficiency and venous thrombo-embolism. A study of three Dutch families. New Engl J Med 1983;309:340.

20.

Kisiel W. Human plasma protein C: Isolation, characterization and mechanism of activation by thrombin. J Clin Invest 1979;64:761.

21.

Owen WG , Esmon CT Functional properties of an endothelial cell cofactor for thrombin catalyzed activation of protein C. J Biol Chem 1981;256:5532.

22.

Marlar RA , Griffin JH Deficiency of protein C inhibitor in combined factor VNIII deficiency disease . J Clin Invest 1980;66:1186.

23.

van der Meer Fjm , van Tilburg NH , van Wijngaarden , et al. A second plasma inhibitor of activation protein C: α1 antitrypsin. Thromb Haemost 1989;63:756.

24.

Heeb MJ , Gruber A. , Griffin JH Metal ion-dependent inhibition of activated protein C (APC) by α2 macroglobulin and α2 antiplasmin in human blood. J Biol Chem 1991;266:17606.

25.

Espana F. , Griffin JH Determination of functional and antigenic protein C inhibitor and its complexes with activated protein C in plasma by Elisa's. Thromb Res 1989;55:671.

26.

Espana F. , Vicente V. , Tabernero D. , et al. Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thromb Res 1990;59:593.